Inhibitor Therapeutics (INTI) Retained Earnings (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Retained Earnings came in at $54.1 million in Q1 2026, up 202.57% YoY from $17.9 million in Q1 2025, and little changed on a QoQ basis from $54.1 million in Q4 2025.
Inhibitor Therapeutics (INTI) Retained Earnings (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Retained Earnings data on file, last reported at $54.1 million in Q1 2026.
- Quarterly Retained Earnings rose 202.57% year-over-year to $54.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.1 million (up 202.57% YoY) and the FY2025 annual result came in at $54.1 million, up 203.82% from the prior year.
- Retained Earnings steadied at $54.1 million in Q1 2026, from $54.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $54.1 million in Q2 2025 to a low of -$58.1 million in Q3 2022.
- A 5-year average of -$8.1 million and a median of -$46.3 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 218.13% — and 2025, when it tumbled 197.53%.
- Tracing INTI's Retained Earnings over 5 years: stood at -$45.8 million in 2022, then soared by 218.13% to $54.0 million in 2023, then tumbled by 196.43% to -$52.1 million in 2024, then surged by 203.82% to $54.1 million in 2025, then changed by 0.0% to $54.1 million in 2026.
- The last three Retained Earnings figures came in at $54.1 million (Q1 2026), $54.1 million (Q4 2025), and $54.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -56.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.11 Mn |
| Dec 31, 2025 | 54.11 Mn |
| Sep 30, 2025 | 54.11 Mn |
| Jun 30, 2025 | 54.11 Mn |
| Mar 31, 2025 | -52.75 Mn |
| Dec 31, 2024 | -52.12 Mn |
| Sep 30, 2024 | -50.70 Mn |
| Jun 30, 2024 | 54.09 Mn |
| Mar 31, 2024 | 54.09 Mn |
| Dec 31, 2023 | 54.05 Mn |
| Sep 30, 2023 | -47.61 Mn |
| Jun 30, 2023 | -46.95 Mn |
| Mar 31, 2023 | -46.29 Mn |
| Dec 31, 2022 | -45.75 Mn |
| Sep 30, 2022 | -58.07 Mn |
| Jun 30, 2022 | -57.95 Mn |
| Mar 31, 2022 | -57.82 Mn |
| Dec 31, 2021 | -57.67 Mn |
| Sep 30, 2021 | -57.59 Mn |
| Jun 30, 2021 | -57.47 Mn |